Sabnis Nirupama, Lacko Andras G
Department of Molecular Biology & Immunology, UNT Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA.
Ther Deliv. 2012 May;3(5):599-608. doi: 10.4155/tde.12.41.
Plasma lipoproteins are transporters of lipids and other hydrophobic molecules in the mammalian circulation. Lipoproteins also have a strong potential to serve as drug-delivery vehicles due to their small size, long residence time in the circulation and high-drug payload. Consequently, lipoproteins and synthetic/reconstituted lipoprotein preparations have been evaluated with increasing interest towards clinical applications, particularly for cancer diagnostics/imaging and chemotherapy. In this review, past and current studies on lipoproteins and similar alternative drug carriers are discussed regarding their suitability as agents to deliver drugs, primarily to cancer cells and tumors. A lipoprotein-based delivery strategy may also provide a novel platform for improving the therapeutic efficacy of drugs that have previously been judged unsuitable or had only limited application due to poor solubility. An additional, and perhaps the most important aspect of the drug-delivery process via lipoprotein-type carriers, is the receptor-mediated uptake of the payload from the lipoprotein complex. Monitoring the expression of specific receptors prior to treatment could, thus, give rise to efficient selection of optimally responsive patients, resulting in a successful personalized therapy regimen.
血浆脂蛋白是哺乳动物循环系统中脂质和其他疏水分子的转运载体。由于其尺寸小、在循环系统中的停留时间长以及药物载量高，脂蛋白还具有很强的作为药物递送载体的潜力。因此，脂蛋白以及合成/重组脂蛋白制剂在临床应用方面的研究越来越受到关注，特别是在癌症诊断/成像和化疗领域。在这篇综述中，我们讨论了过去和当前关于脂蛋白及类似替代药物载体的研究，探讨它们作为药物递送剂，尤其是向癌细胞和肿瘤递送药物的适用性。基于脂蛋白的递送策略还可能为改善那些因溶解度差而先前被判定不适合或应用有限的药物的治疗效果提供一个新的平台。通过脂蛋白型载体进行药物递送过程的另一个或许也是最重要的方面，是药物从脂蛋白复合物中通过受体介导的摄取。因此，在治疗前监测特定受体的表达可以有效筛选出反应最佳的患者，从而制定出成功的个性化治疗方案。
